Assessment of antihistamine use in early pregnancy and birth defects

Journal of Allergy and Clinical Immunology: In Practice

Volumn 1, Issue 6, 2013, Pages 666-674.e1

  Li, Qian ^a   Mitchell, Allen A ^b   Werler, Martha M ^b   Yau, Wai Ping ^a,c   Hernández Díaz, Sonia ^a  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b BOSTON UNIVERSITY   (United States)

^c NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

Antihistamines; Birth defects; First trimester; Maternal exposure

Indexed keywords

ANTIHISTAMINIC AGENT; CETIRIZINE; CHLORPHENIRAMINE; DIMENHYDRINATE; DIPHENHYDRAMINE; DOXYLAMINE; FEXOFENADINE; LORATADINE; PROMETHAZINE;

ADULT; ARTICLE; BIRTH DEFECT; CASE CONTROL STUDY; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG USE; FEMALE; FIRST TRIMESTER PREGNANCY; HUMAN; INFANT; MAJOR CLINICAL STUDY; PRENATAL DRUG EXPOSURE; RISK ASSESSMENT; RISK FACTOR; ABNORMALITIES, DRUG-INDUCED; ADOLESCENT; CLINICAL TRIAL; MULTICENTER STUDY; PREGNANCY; PREGNANCY COMPLICATIONS; YOUNG ADULT;

ABNORMALITIES, DRUG-INDUCED; ADOLESCENT; ADULT; CASE-CONTROL STUDIES; FEMALE; HISTAMINE ANTAGONISTS; HUMANS; PREGNANCY; PREGNANCY COMPLICATIONS; PREGNANCY TRIMESTER, FIRST; RISK FACTORS; YOUNG ADULT;

EID: 84886996446     PISSN: 22132198     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaip.2013.07.008     Document Type: Article

References (47)

1. Hardman J.G., Limbird L.E., Goodman-Gilman A. Goodman & Gilman's The Pharmacological Basis of Therapeutics 2001, McGraw-Hill, New York. 10th ed.
2. Werler M.M., Mitchell A.A., Hernandez-Diaz S., Honein M.A. Use of over-the-counter medications during pregnancy. Am J Obstet Gynecol 2005, 193:771-777.
3. Briggs G.G., Freeman R.K., Yaffe S.J. Drugs in pregnancy and lactation 2002, Lippincott Williams & Wilkins, Philadelphia. 7th ed.
4. Mitchell A.A. Studies of drug-induced birth defects. Pharmacoepidemiology 2012, John Wiley, Chichester, UK. 5th ed. B.L. Strom (Ed.).
5. Aselton P., Jick H., Mulunsky A., Hunter J., Stergacjis A. First-trimester drug use and congenital disorders. Obstet Gynecol 1985, 65:451-455.
6. Brent R.L. Bendectin: review of the medical literature of a comprehensively studied human nonteratogen and the most prevalent tortogen-litigen. Reprod Toxicol 1995, 9:337-349.
7. Evaluation of an association between loratadine and hypospadias-United States, 1997-2201. MMWR Morb Mortal Wkly Rep 2004, 53:219-221. Centers for Disease Control and Prevention.
8. Diav-Citrin O., Shechtman S., Aharonovich A., Moerman L., Arnon J., Wajnberg R., et al. Pregnancy outcome after gestational exposure to loratadine or antihistamines: a prospective controlled cohort study. JAllergy Clin Immunol 2003, 111:1239-1243.
9. Einarson A., Bailey B., Jung G., Spizzirri D., Baillie M., Koren G. Prospective controlled study of hydroxyzine and cetirizine in pregnancy. Ann Allergy Asthma Immunol 1997, 78:183-186.
10. Kallen B., Olausson P.O. No increased risk of infant hypospadias after maternal use of loratadine in early pregnancy. Int J Med Sci 2006, 3:106-107.
11. McKeique P.M., Lamm S.H., Linn S., Kutcher J.S. Bendectin and birth defects: I. A meta-analysis of the epidemiologic studies. Teratology 1994, 50:27-37.
12. McIntyre B.S., Vancutsem P.M., Treinen K.A., Morrissey R.E. Effects of perinatal loratadine exposure on male rat reproductive organ development. Reprod Toxicol 2003, 17:691-697.
13. Moretti M.E., Caprara D., Coutinho C.J., Bar-Oz B., Berkovitch M., Addis A., et al. Fetal safety of loratadine use in the first trimester of pregnancy: a multicenter study. JAllergy Clin Immunol 2003, 111:479-483.
14. Nelson M.M., Forfar J.O. Associations between drugs administered during pregnancy and congenital abnormalities of the fetus. Br Med J 1971, 1:523-527.
15. Paulus W., Schloemp S., Sterzik K., Stoz F. Pregnancy outcome after exposure to cetirizine/levocetirizine in the first trimester-a prospective controlled study. Reprod Toxicol 2004, 19:258. [Abstract].
16. Pedersen L., Nørgaard M., Skriver M.V., Olsen J., Sørensen H.T. Prenatal exposure to loratadine in children with hypospadias: a nested case-control study within the Danish National Birth Cohort. Am J Ther 2006, 13:320-324.
17. Schardein J.L., Hentz D.L., Petrere J.A., Kurtz S.M. Teratogenesis studies with diphenhydramine HCl. Toxicol Appl Pharmacol 1971, 18:971-976.
18. Schatz M., Petitti D. Antihistamines and pregnancy. Ann Allergy Asthma Immunol 1997, 78:157-159.
19. Schwarz E.B., Moretti M.E., Nayak S., Koren G. Risk of hypospadias in offspring of women using loratadine during pregnancy: a systematic review and meta-analysis. Drug Saf 2008, 31:775-788.
20. Seto A., Einarson T., Koren G. Pregnancy outcome following first trimester exposure to antihistamines: meta-analysis. Am J Perinatol 1997, 14:119-124.
21. Shaw G.M., Todoroff K., Velie E.M., Lammer E.J. Maternal illness, including fever and medication use as risk factors for neural tube defects. Teratology 1998, 57:1-7.
22. Weber-Schoendorfer C., Schaefer C. The safety of cetirizine during pregnancy. A prospective observational cohort study. Reprod Toxicol 2008, 26:19-23.
23. Werler M.M., Sheehan J., Mitchell A.A. Maternal medication use and risk of gastroschisis and small intestinal atresia. Am J Epidemiol 2002, 155:26-31.
24. Wilton L.V., Pearce G.L., Martin R.M., Mackay F.J., Mann R.D. The outcomes of pregnancy in women exposed to newly marketed drugs in general practice in England. Br J Obstet Gynaecol 1998, 105:882-889.
25. Saxen I. Cleft palate and maternal diphenhydramine intake. Lancet 1974, 1:407-408.
26. Gilboa S.M., Strickland M.J., Olshan A.F., Werler M.M., Correa A., National Birth Defects Prevention Study Use of antihistamine medications during early pregnancy and isolated major malformations. Birth Defects Res A Clin Mol Teratol 2009, 85:137-150.
27. Kallen B., Olausson P.O. Monitoring of maternal drug use and infant congenital malformations. Does loratadine cause hypospadias?. Int J Risk Saf Med 2001, 14:115-119.
28. Kallen B. Use of antihistamine drugs in early pregnancy and delivery outcome. JMatern Fetal Neonatal Med 2002, 11:146-152.
29. Heinonen O.P., Slone D., Shapiro S. Birth Defects and Drugs in Pregnancy 1977, Publishing Sciences Group, Littleton, Mass.
30. Golding J., Vivian S., Baldwin J. Maternal anti-nauseants and clefts of lip and palate. Hum Toxicol 1983, 2:63-73.
31. Aselton P., Jick H., Chentow S.J., Perera D.R., Hunter J.R., Rothman K.J. Pyloric stenosis and maternal Bendectin exposure. Am J Epidemiol 1984, 120:251-256.
32. Eskenazi B., Bracken M.B. Bendectin (Debendox) as a risk factor for pyloric stenosis. Am J Obstet Gynecol 1982, 144:919-924.
33. Mitchell A.A., Rosenberg L., Shapiro S., Slone D. Birth defects related to Bendectin use in pregnancy. I. Oral clefts and cardiac defects. JAMA 1981, 245:2311-2314.
34. Werler M.M., Shapiro S., Mitchell A.A. Periconceptional folic acid exposure and risk of occurrent neural tube defects. JAMA 1993, 269:1257-1261.
35. Louik C., Lin A.E., Werler M.M., Hernandez-Diaz S., Mitchell A.A. First-trimester use of selective serotonin-reuptake inhibitors and the risk of birth defects. NEngl J Med 2007, 356:2675-2683.
36. Lin K.J., Mitchell A.A., Yau W.P., Louik C., Hernández-Díaz S. Safety of macrolides during pregnancy. Am J Obstet Gynecol 2013, 208:221.e1-221.e8.
37. Yau W.P., Lin K.J., Werler M.M., Louik C., Mitchell A.A., Hernandez-Diaz S. Drug certainty-response in interview-based studies. Pharmacoepidemiol Drug Saf 2011, 20:1210-1216.
38. Ludbrook J. Multiple comparison procedures updated. Clin Exp Pharmacol Physiol 1998, 25:1032-1037.
39. Benjamini Y., Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. JR Stat Soc Series B 1995, 57:289-300.
40. Neutel C.I., Johansen H.L. Measuring drug effectiveness by default: the case of Bendectin. Can J Public Health 1995, 86:66-70.
41. Mitchell A.A., Schwingl P.J., Rosenberg L., Louik C., Shapiro S. Birth defects in relation to Bendectin use in pregnancy. II. Pyloric stenosis. Am J Obstet Gynecol 1983, 147:737-742.
42. Sheffield L.J., Batagol R. The creation of therapeutic orphans-or, what have we learnt from the Debendox fiasco?. Med J Aust 1985, 143:143-147.
43. U.S. Food and Drug Administration. FDA News release. FDA approves Diclegis for pregnant women experiencing nausea and vomiting, April 8, 2013. Available from:. Accessed August 6, 2013. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm347087.htm.
44. Werler M.M., Pober B.R., Nelson K., Holmes L. Reporting accuracy among mothers of malformed and nonmalformed infants. Am J Epidemiol 1989, 129:415-421.
45. Mitchell A.A. Special considerations in studies of drug-induced birth defects. Pharmacoepidemiology 2000, 750-763. John Wiley & Sons, New York, NY. 3rd ed. B.L. Strom (Ed.).
46. Khoury M.J., Erickson J.D., James L.M. Etiologic heterogeneity of neural tube defects: clues from epidemiology. Am J Epidemiol 1982, 115:538-548.
47. Bisceglia M., Galliani C.A., Senger C., Stallone C., Sessa A. Renal cystic diseases: a review. Adv Anat Pathol 2006, 13:26-56.